Latest news with #PaulBrooks
Irish Times
19-06-2025
- Irish Times
Garage forecourt ‘drive-offs' without paying for fuel a daily occurrence, court hears
Fuel 'drive-offs', where motorists leave forecourts without paying, happen at a Dublin filling station every day, a judge has been told in a case in which a van courier successfully sued Circle K for defamation of character, winning €10,000 in damages. Judge Mary O'Malley Costello heard some drivers return to pay their bill when they realise they have made an error, some are never seen again, while others return to pay only when the guards are notified and visit or contact them. Barrister Kevin D'Arcy, counsel for courier Paul Brooks, of Palmerstown Lawns, Palmerstown, Dublin 20, said his client only realised he did not have his wallet with him after he had poured €20 of diesel into his van. Mr D'Arcy, who appeared in the Circuit Civil Court with Mackay Solicitors, said his client had not driven off but had gone into Circle K filling station beside Glasnevin Cemetery on the Finglas Road, Dublin, in May 2020 and told the sales assistant of his dilemma. READ MORE He told her he had forgotten his wallet and would ring his mother so she could pay for the diesel by giving her card details over the phone. Mr Brooks was told Circle K was not set up to take an over-the-phone payment. He told the court he had made an arrangement with the sales lady whereby his mother would call to the filling station the following day and pay for the fuel, which she had done. While he was confident he had such an understanding with Circle K, the sales lady had told the court that Mr Brooks had been told the debt had to be paid that day. Mr Brooks said that a month later he had been embarrassed to hear in a phone call from his sister that gardaí had called to his home inquiring about him and telling his sister and his mother of a fuel drive-off by him. He said his neighbours had seen the gardaí pulling up at his home and making inquiries. Mr Brooks sued Circle K of Circle K House, Beech Hill, Clonskeagh Dublin 4, for defamation of character. His mother had called and paid for the fuel the day after the incident. Judge O'Malley Costello said she found Mr Brooks and his mother and sister, and the Circle K sales lady, to have been honest witnesses. She said it was clearly accepted in its defence by Circle K that the fuel had been paid for on the following day. Somehow the gardaí had not acted on a report until July 9th and had attended at Mr Brooks's home, causing him the difficulties he had complained of in his defamation proceedings. She awarded him €10,000 damages and Circuit Court costs against Circle K. A member of Circle K staff had told Judge O'Malley Costello that drive-offs were an everyday occurrence at the filling station.
BBC News
10-06-2025
- Health
- BBC News
First designs for the new QEH hospital in King's Lynn revealed
First designs for a new hospital will go on display at a series of public events, starting this vision for the new Queen Elizabeth Hospital (QEH) in King's Lynn - which will be built on the current hospital's car park - will include single rooms for all a Reinforced Autoclaved Aerated Concrete (RAAC) hospital, the QEH has been prioritised for rebuild by the national New Hospital new building is being developed using national guidance from the New Hospital Programme, developed in consultation with hundreds of clinicians, healthcare staff and patients across the country, the NHS trust said. Paul Brooks, director of estates and facilities for the new QEH, said the visuals would give people "a feel for how our new, digitally enabled, hospital will function"."I look forward to meeting as many people as possible at these events, updating on our progress towards a New QEH and the work to keep our current site open and providing the best possible care."Attendees will have the chance to hear more about the new multi-storey car park, which is a key enabling project for the new hospital. Peter Cox, programme director for the new hospital, said feedback would shape the hospital's designs "as we do know there are concerns" with the new build."At this stage they are really concept," he said."We will go through a process over the next 12 to 18 months, then have a set of plans that we can go for planning application for."Experts attending meetings will also explain how services will be developed for the new building, including preparing departments for the move and the healthcare innovations being explored to meet the needs of the local population for generations to are being held at seven locations in west Norfolk from 10 June until 21 July. Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Yahoo
23-04-2025
- Business
- Yahoo
CN Bio and Pharmaron Establish Long-Term Strategic Partnership to Develop OOC Technologies on a Global R&D Platform
Partnership to validate and promote the application of CN Bio's PhysioMimix technology, with future opportunities for novel application and assay development CAMBRIDGE, England, April 23, 2025--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio's PhysioMimix® technology across existing applications and collaborate on integrating OOC technologies into its R&D platform. The partnership will also explore the development of new applications to address unmet needs in drug discovery and development. The initial phase of the collaboration will focus on validating CN Bio's PhysioMimix technology for current applications in disease modelling, toxicity testing and absorption, distribution, metabolism and excretion (ADME) studies. Following successful validation, the companies will work together to adopt the platform in priority R&D areas and co-develop novel applications to expand the capabilities of OOC technologies. Pharmaron is a global drug R&D service platform, providing end-to-end services across drug discovery, preclinical, and clinical development. Through the partnership, CN Bio will install PhysioMimix instruments at Pharmaron's facilities across the globe, enabling the joint development of cutting-edge OOC solutions tailored to evolving R&D challenges. Dr Paul Brooks, CEO, CN Bio, said: "Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio in new and existing application areas. By working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before. Dr Tomasz Kostrzewski, CSO, CN Bio, commented: "The developments this partnership will enable are especially important given the recent FDA announcement, outlining their plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models. Our platform is best placed to serve current market gaps including testing for immune-mediated organ damage. Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health." Dr Hua Yang, CSO, Pharmaron, added: "We are committed to continuous innovation that enhances the quality of our services and accelerates drug discovery and development. Organ-on-a-chip technology holds significant potential to advance translational science by improving our understanding of drugability at the preclinical stage. We are pleased to collaborate with CN Bio to explore how this technology can add meaningful value to our partners' development programs." View source version on Contacts Zyme Communications Lily JefferyTel: +44(0)7891477378Email: Sign in to access your portfolio
Business Wire
23-04-2025
- Business
- Business Wire
CN Bio and Pharmaron Establish Long-Term Strategic Partnership to Develop OOC Technologies on a Global R&D Platform
CAMBRIDGE, England--(BUSINESS WIRE)--CN Bio, a leading provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, today announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the life sciences industry. Under the agreement, Pharmaron will validate CN Bio's PhysioMimix ® technology across existing applications and collaborate on integrating OOC technologies into its R&D platform. The partnership will also explore the development of new applications to address unmet needs in drug discovery and development. The initial phase of the collaboration will focus on validating CN Bio's PhysioMimix technology for current applications in disease modelling, toxicity testing and absorption, distribution, metabolism and excretion (ADME) studies. Following successful validation, the companies will work together to adopt the platform in priority R&D areas and co-develop novel applications to expand the capabilities of OOC technologies. Pharmaron is a global drug R&D service platform, providing end-to-end services across drug discovery, preclinical, and clinical development. Through the partnership, CN Bio will install PhysioMimix instruments at Pharmaron's facilities across the globe, enabling the joint development of cutting-edge OOC solutions tailored to evolving R&D challenges. Dr Paul Brooks, CEO, CN Bio, said: 'Pharmaron is a global, premier and trusted service provider for the life sciences industry. As such, Pharmaron were the ideal partner for CN Bio as we look to accelerate the growth of our OOC solutions portfolio in new and existing application areas. By working closely together and leveraging the industry-leading expertise of each company, we can share resources that enable us to progress new, innovative solutions from concept to global market deployment more effectively than ever before. Dr Tomasz Kostrzewski, CSO, CN Bio, commented: ' The developments this partnership will enable are especially important given the recent FDA announcement, outlining their plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models. Our platform is best placed to serve current market gaps including testing for immune-mediated organ damage. Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health.' Dr Hua Yang, CSO, Pharmaron, added: ' We are committed to continuous innovation that enhances the quality of our services and accelerates drug discovery and development. Organ-on-a-chip technology holds significant potential to advance translational science by improving our understanding of drugability at the preclinical stage. We are pleased to collaborate with CN Bio to explore how this technology can add meaningful value to our partners' development programs.'
